Francisco Javier Bautista-Paloma

Francisco Javier Bautista-Paloma

Auto-generated profile, based on publicly available information

Francisco Javier Bautista-Paloma

Hospital Universitario Virgen del Rocío

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Revista Española de Anestesiología y Reanimación
Verified
Journal Article
Open access
SLS.R. Leal-Noval
S.R. Leal-Noval
MMM. Muñoz
M. Muñoz
MAM. Asuero
M. Asuero
ECE. Contreras
E. Contreras
JGJosé Antonio García-Erce
José Antonio García-Erce
APA. Puppo
A. Puppo
Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: "Does this particular AABT reduce the transfusion rate or not?" All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) methodology.

26 February 2013 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
MGM. Galván-Banqueri
M. Galván-Banqueri
RGR. Marín Gil
R. Marín Gil
BSBernardo Santos-Ramos
Bernardo Santos-Ramos
FPF. J. Bautista Paloma
F. J. Bautista Paloma
What is known and Objective Psoriasis is a chronic skin disease for which there is an increasing range of treatment options. Biological agents (ustekinumab, adalimumab, infliximab and etanercept) are indicated for moderate‐to‐severe plaque‐type psoriasis in adults who fail to respond to, have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA Unfortunately, with new drugs, the pivotal trials leading to their licensing are often placebo‐controlled trials rather than comparative trials vs. established therapies. Therefore, inference on comparative effectiveness of the newer agents must be derived indirectly, through estimation of effects of the new agents vs. a common comparator. The objective of this study is to compare the relative efficacy of the biological agents through a systematic review of the indirect clinical trial evidence. Methods A systematic literature search was performed for clinical trials of biological agents in psoriasis. Pivotal, randomized, double‐blind, controlled (placebo) trials using intention‐to‐treat analysis were selected for detailed analysis. Trials must include PASI 75 as a primary end point. The indirect comparison was performed using the method of Bucher adjusted with the ITC calculator (Indirect Treatment Comparisons of the Canadian Agency for Drugs and Technologies in Health), etanercept being the reference drug. We defined delta value for therapeutic equivalence as a difference in the efficacy of 25% among the different treatment options. Results and Discussion Fourteen studies (four for ustekinumab, three for adalimumab, three for infliximab and four for etanercept) were included. The indirect comparison results reveal that ustekinumab, adalimumab and infliximab were statistically superior to etanercept with an absolute risk difference for PASI 75 of 12% (95% CI = 5·9–18%), 11% (95% CI = 5·3–16·7%) and 24% (29·7–18·3%) respectively. However, in all situations, the 95% confidence interval does not achieve clinical relevance as no delta exceeds the previously set value (25%). What is new and Conclusion Ustekinumab, adalimumab, infliximab and etanercept can be regarded as clinical equivalents for the treatment of psoriasis. Choice between these agents therefore depends on their relative safety profiles, individual contra‐indications and cost effectiveness.

16 October 2015 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
JCJesús Cotrina-Luque
Jesús Cotrina-Luque
MGMaria Victoria Gil-Navarro
Maria Victoria Gil-Navarro
HAHéctor Acosta-García
Héctor Acosta-García
ELEva Rocío Lara
Eva Rocío Lara
RLRafael Luque-Márquez
Rafael Luque-Márquez
FBFrancisco Javier Bautista-Paloma
Francisco Javier Bautista-Paloma

1 May 2013 in Medicina Intensiva (English Edition)
Verified
Journal Article
Open access
SLS.R. Leal-Noval
S.R. Leal-Noval
MMM. Muñoz
M. Muñoz
MAM. Asuero
M. Asuero
ECE. Contreras
E. Contreras
JGJosé Antonio García-Erce
José Antonio García-Erce
APA. Puppo
A. Puppo
Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: « Does this particular AABT reduce the transfusion rate or not?» All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) methodology.

4 March 2014 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
MPMaria Antonia Pérez-Moreno
Maria Antonia Pérez-Moreno
MGMercedes Galván-Banqueri
Mercedes Galván-Banqueri
SFSandra Flores-Moreno
Sandra Flores-Moreno
AVAngela Maria Villalba-Moreno
Angela Maria Villalba-Moreno
JCJesús Cotrina-Luque
Jesús Cotrina-Luque
FBFrancisco Javier Bautista-Paloma
Francisco Javier Bautista-Paloma

1 March 2010 in Farmacia Hospitalaria
Verified
Journal Article
Open access
ELEva Rocío Lara
Eva Rocío Lara
MGM. Galván-Banqueri
M. Galván-Banqueri
EPElena Prado-Mel
Elena Prado-Mel
BSBernardo Santos-Ramos
Bernardo Santos-Ramos
JVJ.M. Varela-Aguilar
J.M. Varela-Aguilar
FPF.J. Bautista Paloma
F.J. Bautista Paloma
The purpose of this study is to describe the structure of the CFyT, the Pharmacy and Therapeutics Committee, and a tertiary hospital's selection process for new drugs. All annals of the P&TC and the New Drug Incorporation Guides (GINF) to incorporate new drugs received at Hospital Virgen del Rocío between 2004 and 2007 were reviewed. We carried out a descriptive study which collected variables having to do with the drug (drug type, type of register, route of administration and legal category), the petitioner (responsible division, professional category and request type) and the result of the evaluation (final decision, elapsed time between the request and the decision). Of the 72 requested drugs, 45 (62.5%) were approved: six as equivalent treatments, 36 (80%) with specific recommendations, and three (4.2%) with no restrictions. Twelve drugs (81.1%) were not included due to insufficient evidence of their effectiveness compared with the current treatment. The most frequently-requested drug type was the antineoplastics, most commonly requested by Oncology and Haematology divisions. We highlight the fact that many of the petitioners included clinical trials (97.2%) and data referring to costs (84.7%). There is a high level of compliance with the GINF guide in our centre, which guarantees that the P&TC's final decision is based on scientific evidence.